Table 2.
COVID-19 course, treatment and complications in Israeli AIIRD patients.
| Variable * | 1st-3rd outbreaks n=302 | 4th (Delta/vaccinated) outbreak n=110 | All n=412 |
|---|---|---|---|
| Severity n (%) | |||
| Mild | 196 (64.9) | 79 (71.8) | 274 (66.5) |
| Moderate | 33 (10.9) | 15 (13.6) | 48 (11.7) |
| Severe | 73 (24.2) | 16 (14.5) | 89 (21.6) |
| Hospitalization | 161 (53.3) | 29 (26.4) | 190 (46.1) |
| Intubation | 23 (7.6) | 6 (5.5) | 29 (7.0) |
| Non-invasive oxygen supplementation | 53 (17.5) | 16 (14.5) | 69 (16.7) |
| COVID-19 specific Tx | 109 (36.1) | 34 (30.9) | 143 (34.7) |
| Antiviral (remdesivir) | 26 (8.6) | 4 (3.6) | 30 (7.3) |
| Convalescent plasma | 12 (4.0) | 2 (1.8) | 14 (3.4) |
| Antibiotic tx. | 34 (11.3) | 11 (10.0) | 45 (10.9) |
| HCQ | 6 (2.0) | 1 (0.9) | 7 (1.7) |
| LMWH | 71 (23.5) | 20 (18.2) | 91 (22.1) |
| Corticosteroids | 74 (24.5) | 22 (20.0) | 96 (23.3) |
| Biologic medication (tocilizumab/baricitinib) | 5 (1.7) | 3 (2.7) | 8 (1.9) |
| Casirivimab and imdevimab | 5 (1.7) | 14 (12.7) | 19 (4.6) |
| Rheumatic Tx. discontinued | 102 (33.8) | 36 (32.7) | 138 (33.5) |
| COVID-19 complications | 52 (17.2) | 13 (11.8) | 65 (15.8) |
| Secondary bacterial infection | 20 (6.6) | 9 (8.2) | 29 (7.0) |
| Myocarditis | 6 (2.0) | 3 (2.7) | 9 (2.2) |
| Acute kidney injury | 7 (2.3) | 1 (0.9) | 8 (1.9) |
| Thromboembolism | 2 (0.7) | 4 (3.6) | 6 (1.5) |
| Pneumonia | 67 (22.2) | 6 (5.5) | 73 (17.7) |
| Other complication | 21 (7.0) | 4 (3.6) | 25 (6.1) |
| Days hospitalized median(IQR) | 6 (2,14) | 0 (0,3) | 4 (0,14) |
| Mortality | 27 (8.9) | 7 (6.4) | 34 (8.3) |
| Disease activity before COVID-19 (N=400) | 134 out of 300 (44.7) | 34 out of 100 (34) | 168 (42.0) |
| Disease activity after COVID-19 (N=344) | 60 out of 265 (22.6) | 25 out of 79 (31.6) | 85 (24.7) |
*Categorical variables are presented as number (%). COVID-19, coronavirus disease 2019; AIIRD, autoimmune inflammatory rheumatic disease; n, number; tx, treatment; HCQ, hydroxychloroquine; LMWH, low molecular weight heparin; IQR, interquartile range.